HealthcareServices

Hereditary Angioedema Market Outlook: Growth and Forecast Highlights 2030

February 25, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the hereditary angioedema market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Hereditary Angioedema Market show for the 2026–2030 period?

The hereditary angioedema market has shown robust growth in recent years. It is anticipated to expand from $2.81 billion in 2025 to $3.04 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.2%. This historical expansion can be attributed to several factors including heightened clinical awareness of rare genetic disorders, the widespread availability of plasma-derived C1 esterase inhibitors, an increase in specialty treatment centers, enhanced diagnostic accuracy for HAE, and burgeoning patient advocacy initiatives.

The hereditary angioedema market is projected to experience robust expansion over the coming years. By 2030, this market is anticipated to reach $4.15 billion, demonstrating a compound annual growth rate (CAGR) of 8.0%. Factors contributing to this growth during the forecast period include the broader availability of new oral and subcutaneous treatments, increased funding for rare disease drug research, a greater embrace of personalized medical strategies, the expansion of genetic screening initiatives, and enhanced long-term disease management protocols. Key trends anticipated during this period involve a greater uptake of specific bradykinin-targeting treatments, an increase in the application of preventive treatment plans, an intensified emphasis on early genetic detection, the proliferation of self-administered therapies at home, and more refined patient-focused treatment methodologies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22002&type=smp

What Drivers Are Shaping The Development Of The Hereditary Angioedema Market?

The increasing occurrence of rare diseases is projected to drive the expansion of the hereditary angioedema market in the future. Rare diseases, also known as orphan diseases, refer to health conditions that impact a small segment of the population. The rise in the prevalence of rare diseases is influenced by multiple factors, including progress in medical research, shifts in population demographics, and environmental effects. Hereditary angioedema (HAE) is a significant rare disease, underscoring the demand for specialized treatments and awareness due to its dangerous swelling episodes. Its infrequent nature and genetic basis make prompt diagnosis and targeted therapies vital for effective management and improved patient results. For instance, in January 2025, The American Cancer Society, a US-based professional organization, estimated that by 2025, 59,660 new cases of oral cavity and oropharyngeal cancer are expected to be diagnosed, and approximately 12,770 people are projected to die from these cancers. Consequently, the growing prevalence of rare diseases is fueling the growth of the hereditary angioedema market.

What Segment Types Are Examined In The Hereditary Angioedema Market?

The hereditary angioedema market covered in this report is segmented –

1) By Type: Hereditary Angioedema Type I, Hereditary Angioedema Type II

2) By Treatment Type: Prophylaxis, On-demand

3) By Drug Class: C-1 Esterase Inhibitors, Bradykynin Receptor Antagonist, Kallikrein Inhibitors, Other Drug Classes

4) By Route Of Administration: Subcutaneous, Intravenous, Oral

5) By Distribution channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Hereditary Angioedema Type I: C1-Inhibitor Deficiency, Low C1-Inhibitor Levels

2) By Hereditary Angioedema Type II: Normal C1-Inhibitor Levels, Dysfunctional C1-Inhibitor, Genetic Mutations In SERPING1 Gene

What Industry Trends Are Transforming The Hereditary Angioedema Market?

Key companies in the hereditary angioedema market are developing innovative products, such as oral plasma kallikrein inhibitors, to offer patients more convenient and effective on-demand treatment options. Oral plasma kallikrein inhibitors are drugs that block plasma kallikrein to prevent excessive bradykinin production, primarily used for treating hereditary angioedema. For instance, in September 2024, KalVista Pharmaceuticals, Inc., a US-based pharmaceutical company, announced that the FDA has accepted its new drug application (NDA) for sebetralstat. This investigational oral plasma kallikrein inhibitor is intended for the on-demand treatment of hereditary angioedema (HAE) attacks in both adult and pediatric patients aged 12 and older. Sebetralstat provides a new treatment approach by targeting and inhibiting plasma kallikrein activity. The acceptance of the NDA represents a major milestone toward potential approval and commercialization.

Who Are The Major Companies Operating In The Hereditary Angioedema Market?

Major companies operating in the hereditary angioedema market are Takeda Pharmaceutical Company Limited, CSL Limited, Sanofi S.A., Pharming Group N.V., BioCryst Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intellia Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Astria Therapeutics Inc., Pharvaris N.V., Adverum Biotechnologies Inc., ADARx Pharmaceuticals Inc., Attune Pharmaceuticals Inc., Lev Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., Spark Therapeutics Inc., Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Hereditary Angioedema Market?

North America was the largest region in the hereditary angioedema market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Hereditary Angioedema Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22002&type=smp

Browse Through More Reports Similar to the Global Hereditary Angioedema Market 2026, By The Business Research Company

Biopsy Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Angina Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-global-market-report

Angina Pectoris Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795